| Literature DB >> 27322029 |
Hiroyuki Kato1,2, Katsuya Suzuki1, Makoto Bannai1, Daniel R Moore2.
Abstract
UNLABELLED: A higher protein intake has been recommended for endurance athletes compared with healthy non-exercising individuals based primarily on nitrogen balance methodology. The aim of this study was to determine the estimated average protein requirement and recommended protein intake in endurance athletes during an acute 3-d controlled training period using the indicator amino acid oxidation method. After 2-d of controlled diet (1.4 g protein/kg/d) and training (10 and 5km/d, respectively), six male endurance-trained adults (28±4 y of age; Body weight, 64.5±10.0 kg; VO2peak, 60.3±6.7 ml·kg-1·min-1; means±SD) performed an acute bout of endurance exercise (20 km treadmill run) prior to consuming test diets providing variable amounts of protein (0.2-2.8 g·kg-1·d-1) and sufficient energy. Protein was provided as a crystalline amino acid mixture based on the composition of egg protein with [1-13C]phenylalanine provided to determine whole body phenylalanine flux, 13CO2 excretion, and phenylalanine oxidation. The estimated average protein requirement was determined as the breakpoint after biphasic linear regression analysis with a recommended protein intake defined as the upper 95% confidence interval. Phenylalanine flux (68.8±8.5 μmol·kg-1·h-1) was not affected by protein intake. 13CO2 excretion displayed a robust bi-phase linear relationship (R2 = 0.86) that resulted in an estimated average requirement and a recommended protein intake of 1.65 and 1.83 g protein·kg-1·d-1, respectively, which was similar to values based on phenylalanine oxidation (1.53 and 1.70 g·kg-1·d-1, respectively). We report a recommended protein intake that is greater than the RDA (0.8 g·kg-1·d-1) and current recommendations for endurance athletes (1.2-1.4 g·kg-1·d-1). Our results suggest that the metabolic demand for protein in endurance-trained adults on a higher volume training day is greater than their sedentary peers and current recommendations for athletes based primarily on nitrogen balance methodology. TRIAL REGISTRATION: ClinicalTrial.gov NCT02478801.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27322029 PMCID: PMC4913918 DOI: 10.1371/journal.pone.0157406
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart of the trials.
Protein intakes used in individual subjects.
Participants consumed each protein intake which ranged from 0.2 to 2.8 g·kg-1·d-1, for a total of 34 trials.
| Subject No. | Test protein intakes, g·kg-1·d-1 |
|---|---|
| 1 | 0.2, 0.9, 1.3, 1.65, 1.8, 2.3, 2.8 |
| 2 | 0.8, 1.15 |
| 3 | 0.4, 1.0, 1.6, 2.0, 2.65 |
| 4 | 0.45, 0.7, 1.05, 1.45, 1.7, 2.35, 2.5 |
| 5 | 0.5, 0.6, 1.4, 1.95, 2.25, 2.6 |
| 6 | 0.25, 0.85, 1.2, 1.5, 1.75, 2.15, 2.75 |
Amino acid composition of reference protein and selected test protein intakes.
| Reference protein | 0.2 g protein·kg-1·d-1 | 0.7 g protein·kg-1·d-1 | 1.2 g protein·kg-1·d-1 | 1.7 g protein·kg-1·d-1 | 2.2 g protein·kg-1·d-1 | 2.8 g protein·kg-1·d-1 | |
|---|---|---|---|---|---|---|---|
| L-Alanine | 61.5 | 12.3 | 43.1 | 73.8 | 104.6 | 135.3 | 172.2 |
| L-arginine HCL | 75.1 | 15.0 | 52.6 | 90.1 | 127.7 | 165.2 | 210.3 |
| L-Asparagine | 33.3 | 6.7 | 23.3 | 40.0 | 56.6 | 73.3 | 93.2 |
| L-Aspartic acid | 33.3 | 6.7 | 23.3 | 40.0 | 56.6 | 73.3 | 93.2 |
| L-Cysteine | 22.1 | 4.4 | 15.5 | 26.5 | 37.6 | 48.6 | 61.9 |
| L-Glutamine | 56.6 | 11.3 | 39.6 | 67.9 | 96.2 | 124.5 | 158.5 |
| L-Glutamic acid | 56.6 | 11.3 | 39.6 | 67.9 | 96.2 | 124.5 | 158.5 |
| L-Glycine | 33.3 | 6.7 | 23.3 | 40.0 | 56.6 | 73.3 | 93.2 |
| L-Histidine | 22.7 | 4.5 | 15.9 | 27.2 | 38.6 | 49.9 | 63.6 |
| L-Isoleucine | 62.8 | 12.6 | 44.0 | 75.4 | 106.8 | 138.2 | 175.8 |
| L-leucine | 83.3 | 16.7 | 58.3 | 100.0 | 141.6 | 183.3 | 233.2 |
| L-Lysine HCL | 75.7 | 15.1 | 53.0 | 90.8 | 128.7 | 166.5 | 212.0 |
| L-Methionine | 29.6 | 5.9 | 20.7 | 35.5 | 50.3 | 65.1 | 82.9 |
| L-Phenylalanie | 54.7 | 30.5 | 30.5 | 30.5 | 30.5 | 30.5 | 30.5 |
| L-Proline | 41.9 | 8.4 | 29.3 | 50.3 | 71.2 | 92.2 | 117.3 |
| L-serine | 83.9 | 16.8 | 58.7 | 100.7 | 142.6 | 184.6 | 234.9 |
| L-threonine | 47.1 | 9.4 | 33.0 | 56.5 | 80.1 | 103.6 | 131.9 |
| L-tryptophan | 15.6 | 3.1 | 10.9 | 18.7 | 26.5 | 34.3 | 43.7 |
| L-Tyrsoine | 40.7 | 40.0 | 40.0 | 40.0 | 40.0 | 40.0 | 40.0 |
| L-Valine | 70.3 | 14.1 | 49.2 | 84.4 | 119.5 | 154.7 | 196.8 |
1 Participants consumed a single protein intake that ranged from 0.2 to 2.8 g·kg-1·min-1, on each metabolic trial.
2 Represents egg protein composition.
3 Actual concentration of amino acid in HCl form in amino acid mixture; arginine, 62.1 mg·g-1; and lysine 60.6 mg·g-1.
4 Phenylalanine intake was held constant at 30.5 mg·kg-1·d-1 for all protein intakes.
5 Tyrosine intake was held constant at 40.0 mg·kg-1·d-1 for all protein intakes
Characteristics of participants.
| Mean ± SD | |
|---|---|
| Age, yr | 28.3 ± 4.2 |
| Height, cm | 173.3 ± 4.0 |
| Body weight, kg | 64.5 ± 10.0 |
| Fat-free mass, kg | 56.5 ± 7.1 |
| VO2peak, ml/kg/min | 60.3 ± 6.7 |
| REE, Kcal/day | 1624.1 ± 274.3 |
Summary of the endurance exercise stimulus in individual subjects.
Values are means ± SD.
| Subject No. | Duration (min) | Intensity (%HR max) | Exercise-induced energy expenditure (Kcal) |
|---|---|---|---|
| 1 | 96.1 ± 3.9 | 65.9 ± 3.5 | 878 ± 69 |
| 2 | 90.5 ± 4.9 | 71.3 ± 2.5 | 939 ± 112 |
| 3 | 90.8 ± 1.6 | 82.3 ± 3.3 | 1264 ± 80 |
| 4 | 91.4 ± 2.4 | 79.6 ± 1.7 | 1327 ± 68 |
| 5 | 102.2 ± 1.6 | 70.9 ± 3.8 | 1110 ± 109 |
| 6 | 118.3 ± 5.1 | 78.4 ± 2.4 | 1209 ± 50 |
1: Average time to complete 20 km on each metabolic trial.
2: %HRmax (average HR/Predicted HR max) during 20-km run.
3: Energy expenditure during endurance exercise = Maximal energy expenditure (kcal/min)* [(% HRmax) * 1.4301–47.755]*time (min)
Fig 2Relationship between Phenylalanine Ra and protein intake after exercise stimulus.
Each data point represents PheRa on the individual metabolic trial day. The slope of regression line was not significantly different from zero (P = 0.11).
The effect of protein intake on phenylalanine fluxes.
Values are means ± SD. No significant differences (P > 0.05) in phenylalanine flux were observed within each participant because of various test protein intakes.
| Subject No. | Phenylalanine flux (μmol·kg-1·h-1) |
|---|---|
| 1 | 65.3 ± 5.7 |
| 2 | 74.1 ± 6.3 |
| 3 | 63.5 ± 10.7 |
| 4 | 73.7 ± 7.2 |
| 5 | 74.8 ± 7.2 |
| 6 | 64.6 ± 7.6 |
Fig 3Relationship between protein intake and F13CO2.
6 participants completed 34 metabolic trials with a range of test protein intake (0.2–2.8 g·kg-1·d-1). The breakpoint represented the average protein requirement. The breakpoint was determined by using a biphasic linear regression crossover analysis. The average protein requirement and recommended protein intakes were estimated to be 1.65, 1.83 g·kg-1·d-1 respectively (R2 = 0.86).
Fig 4Relationship between protein intake and PheOx.
6 participants completed 34 metabolic trials with a range of test protein intake (0.2–2.8 g·kg-1·d-1). The breakpoint estimated the average protein requirement. The breakpoint was determined by using a biphasic linear regression crossover analysis. The average protein requirement and recommended protein intake were estimated to be 1.53, 1.70 g·kg-1·d-1 respectively (R2 = 0.85).